glp-1 and parkinson's Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep Role of glucagon-like peptide-1 receptor

The key is that success isnt just about the number on the scale

Since the discovery of ferroptosis, an increasing number of drugs have been shown to exert their efficacy by regulating ferroptosis

Neutrophil invasion is a typical feature in inflammation (Atroshi et al

These programs often provide significant cost reductions, and for insured patients, copay assistance can lower monthly expenses to between $25 and $200

To find out more information about Wegovy and other GLP-1s, take a look at our blog post on the differences between Mounjaro / Zepbound and Ozempic

Two people with UHC cards can have completely different coverage for the same medication